In the Zone

 $CVAC – CureVac N.V. 

 

CureVac BV is a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. It’s lead clinical programs that includes a Phase I clinical trial for the treatment of various types of solid tumors; as well as a Phase I clinical trial for vaccination against rabies. It is also advancing a mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial.

The company is headquartered in Germany. CureVac BV is a recent (IPO) Initial Public Offering that trades on the Nasdaq. The company was priced at the top of the expected range of $14 to $16, but began the day trading at $44 and ended the day trading at $55.90 up +39.90 or 249.38 percent on volume if 23,676,194. 

 

This stock is not a buy recommendation, please do your own due diligence or get help from a professional before trading. 

By Marlin Rolle